Navigation Links
Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
Date:9/1/2008

GOTEBORG, Sweden, September 1 /PRNewswire/ -- Calabar AB, a privately held pharmaceutical company developing therapies for treating dry mouth, today announced a EUR 350,000 equity financing from the investment company Karolinska Development AB. The financing will take Calabar's product through a phase II study with repeated dosing. "We believe the unique local action of the drug on the minor glands will lead to improved outcomes in patients with dry mouth and we look forward to its continued development," remarked VP Business Development, Fredrik Rook of Calabar AB. "Dry mouth is affecting millions of people every day and there is a great unmet need for new drugs in this area."

The active drug, physostigmine, a cholinesterase inhibitor, targets the minor salivary glands with a direct local action, inducing a more lubricating saliva. In previous phase II studies with single dosing, the locally administered drug proved to significantly increase the salivary flow in patients suffering from dry mouth.

"This will take treatment of dry mouth symptoms to a new level," concludes Mr. Rook.

About Calabar

Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia "dry mouth". The company develops locally administered formulations of the cholinesterase inhibitor physostigmine, which has been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The company is part of the Karolinska Development AB portfolio. For more information, please visit http://www.calabar.se

Investor and Media Contact

Fredrik Rook,

+46-8-524-860-38,

fredrik.rook@calabar.se .


'/>"/>
SOURCE Calabar AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
2. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
3. 454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
4. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
5. PRoFESS(R) Results Announced at XVII European Stroke Conference
6. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
7. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
8. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
9. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
10. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
11. Light Sciences Oncology Raises $40.1 Million in Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)...  Novavax, Inc., (Nasdaq: NVAX ) today announced ... of its RSV F protein recombinant nanoparticle vaccine candidate (RSV ... published in the journal Vaccine (the ... scientific conferences). The Company previously announced top line results ... the RSV F Vaccine with the goal of protecting infants ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq: ... care, today announced new findings demonstrating positive biochemical outcomes ... System One™. The data will be presented at ... Madrid, Spain . ... Improve Home Dialysis Network in Europe ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... , ... Create a feel-good lyric music video in Final Cut Pro X with ProLyric from ... write in the lyrics to any song. ProLyric flies in the text for each section ... can be added modularly for optimal control. ProLyric makes editing any music video or text-based ...
(Date:6/25/2017)... ... , ... With a heatwave currently bearing down on Northern California pushing temperatures to the maximum, ... ready is easy with laser hair removal. , The process of summer waxing and ... when all you want to do is get out, dive in and cool off. There ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable ... that visits to the dentist fit into their patients’ busy lifestyles. Dental365 also ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The ... will ultimately do significant harm to people with all chronic conditions, including mental ... it leaves in place the Affordable Care Act (ACA) requirement that insurers cover ...
(Date:6/23/2017)... ... 23, 2017 , ... The Military Officers Association of America (MOAA) announced its ... Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the staff ... intimacy with the issues and challenges veterans face with the VA. Following a 30-year ...
Breaking Medicine News(10 mins):